• Robust 20-week data from Phase 1b APEX • MOA validated by scientific community • Phase 3 PEAK and PINNACLE topline data expected in 4Q 2026 and 2Q 2027 • Commercial opportunity of 150,000+ initial addressable patients with headroom • Science-based “heavyweights” • Tarcocimab: targeting BLA mid-2026 in wet AMD, RVO and diabetic retinopathy • KSI-501: bispecific ABC ® may be even better! • KSI-102, KSI-103: bispecifics for inflammation • Duets for glaucoma and geographic atrophy • VETi: AI headsets for commercial leadership • URSUS: commercial manufacturing A potent reason to believe in Kodiak 2 options in the $15+ billion anti-VEGF market Accelerating our technology and pipeline leadership KSI-101 Tarcocimab & KSI-501 Pipeline, Digital Health, Manufacturing Wholly Owned We are a precommercial, retina-focused biotech on the move 3 AMD: age-related macular degeneration; RVO: retinal vein occlusion; ABC: antibody biopolymer conjugate